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Abstract The present study has explored T cell antigen
receptor-regulated serine kinases in human T cells. The results
identify two phosphatidylinositol 3-kinase (PI3K)-controlled
serine kinases operating downstream of the T cell receptor
(TCR) in primary T cells : (i) protein kinase B whose activation
regulates the phosphorylation of glycogen synthase kinase 3 and
(ii) ribosomal S6 kinase 1, a kinase with a critical role in the
regulation of protein synthesis and cell growth. T cells express
two isoforms of S6k1: a 70 kDa cytoplasmic kinase and an
85 kDa isoform that has a classic nuclear localisation. TCR
ligation triggers a parallel engagement of both the 70 and 85 kDa
isoforms of S6k1 in a response that requires PI3K func-
tion. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The T cell antigen receptor (TCR) coordinates activation of
T cells in response to foreign antigen. It initiates intracellular
signalling by recruiting and activating protein tyrosine kinases
of the Src, ZAP70/Syk and Tec families [1,2]. TCR triggering
regulates inositol lipid turnover and induces an elevation in
intracellular concentrations of the products of phosphatidyl-
inositol 3-kinase (PI3K), PI(3,4,5)P3 and PI(3,4P)2 [3]. The
biochemistry of the mechanisms that link the TCR to PI3Ks
has been the subject of investigation [4,5] but the downstream
targets for the lipid products of PI3K in TCR signalling are
not fully understood. Nevertheless, experiments with PI3K
inhibitors indicate that PI3K-regulated signalling pathways
are important for lymphocyte activation [6]. Targets for the
binding of PI(3,4,5)P3 are Tec family tyrosine kinases and
guanine nucleotide exchange proteins such as Vav-1 and
Vav-2 [7]. There are also two serine/threonine kinases that
bind PI(3,4,5)P3; the phosphoinositide-dependent protein ki-
nase PDK-1 and protein kinase B (PKB) [8^9]. PDK1 phos-
phorylates key residues in the activation loops of several ser-
ine kinases including members of the protein kinase C super-
family of kinases PKC K and j, the ribosomal S6 kinase
(S6k), S6k1 and the serine/threonine kinase PKB [10^12].
We have previously shown that ligation of the TCR com-
plex can modulate PKB activity in the T leukaemic cell line
Jurkat [13^15]. However, Jurkat cells do not express the phos-
phoinositide lipid 3-phosphatase PTEN and consequently they
have high constitutive levels of PI(3,4,5)P3 and constitutive
basal activation of PI3K-dependent downstream e¡ectors
[16]. The key questions are whether TCR ligation can regulate
the activity of two major PI3K-regulated serine kinase PKB
and p70 S6k1 in primary T cells. The relevance of this ques-
tion stems from the many signi¢cant functions ascribed to
PKB and S6k1 and the importance of understanding exactly
when these kinases are switched on during the life span of a
T lymphocyte: for example, S6K1 is important for the regu-
lation of protein synthesis and the control of cell growth
[17,18] ; PKB has been shown to play an important role in
the maintenance of cell survival [19,20]. Moreover, PKB can
stimulate the activity of necrosis factor UB (NFUB) transcrip-
tion factors and E2F transcription factors [21,22] ; the latter
are important components of the mechanisms that control the
mammalian cell cycle. PKB also phosphorylates and inacti-
vates glycogen synthase kinase-3 (GSK3) [23] an enzyme
which promotes the nuclear export of the nuclear factor of
activated T cells (NFAT) [24], a transcription factor involved
in cytokine gene induction.
In the present study we explore the ability of the TCR
complex to regulate PKB and p70 S6k activity in human
peripheral blood-derived T lymphocytes. The data show that
ligation of the TCR induces a rapid and strong activation of
PKB and a slower but strong activation of p70 S6k. These
responses are PI3K-dependent revealing that PI3K couples
the TCR to two biologically important serine kinases.
2. Materials and methods
2.1. Chemicals and reagents
Recombinant IL-2 was from Chiron, Emeryville, CA, USA,
LY294002 from Calbiochem, Nottingham, UK, ERK2 antibodies
from Transduction laboratories, UK, anti-phosphoserine 473 PKB
and anti-PKB from New England Biolabs, Beverly, MA, USA.
Anti-phospho GSK3K and anti-pan GSK3 were from UBI, Lake
Placid, NY, USA. Rapamycin and p70S6 kinase 1 antibodies were a
generous gift from G. Thomas. Horseradish peroxidase-conjugated
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anti-mouse Ab and anti-rabbit Ab were from Amersham (Paris,
France).
2.2. Cell culture and stimulation
T lymphocytes were prepared from peripheral blood mononuclear
cells isolated from healthy donors. Human T lymphoblasts were gen-
erated as described [5] and maintained in RPMI 1640 supplemented
with 10% foetal calf serum, 2 mM glutamine and IL-2 (20 ng/ml) at
37‡C and 5% CO2. T lymphoblasts were quiesced by washing three
times, and replacing in RPMI 1640 with 10% serum in the absence of
IL-2 for 48 h. The inhibitors LY294002 (5 WM) and rapamycin (20 ng/
ml) were pre-incubated with cells for 30 min prior to TCR or IL-2
stimulation. Human T lymphocytes were stimulated via the TCR
complex by treatment with 10 Wg/ml of the CD3 antibody UCHT1
and by 20 ng/ml of IL-2 via the IL-2 receptor at the indicated times.
2.3. Cell extract preparation and Western blot analysis
After stimulation, cells were lysed (5U106 per ml) in lysing bu¡er
described in [26]. Proteins were separated by SDS^PAGE using the
following gel conditions: for PKB and GSK3, 7.5% acrylamide/0.2%
bis-acrylamide; for S6 kinase, 10% acrylamide/0.1% bis-acrylamide.
Proteins were transferred to PVDF membranes (Millipore) and de-
tected by Western blot with the indicated antibodies (utilised dilutions
following manufacturer’s instructions for phospho PKB (1:1000), pan
PKB (1:1000), phospho GSK3K (1:1000), pan GSK3 (1:1000), S6
kinase antibody (1:5000). Immunoreactive bands were visualised
with the chemiluminescence Western blotting system (Amersham).
3. Results
3.1. TCR triggering activates PKB and regulates serine
phosphorylation of the PKB substrate GSK3
Stimulation of PKB catalytic function requires its phos-
phorylation on threonine 308 and serine 473, a response medi-
ated by a PI3K-dependent protein kinase PDK1. To examine
the e¡ects of triggering the TCR complex on the activity of
PKB, primary human T lymphocytes were activated with the
anti-CD3 antibody UCHT1 at di¡erent times. Total cell ex-
tracts were fractionated by SDS^PAGE and processed for
Western blot analysis with a speci¢c antisera that recognises
active PKB molecules phosphorylated on serine 473. The anti-
phospho PKB antibody did not react with PKB present in cell
lysates from quiescent human primary T cells whereas it
strongly reacted with those from cells activated by crosslink-
ing the TCR with UCHT1 (Fig. 1A). Maximal stimulation of
PKB phosphorylation was observed within 5 min of stimula-
tion and was sustained by 30 min. A similar pattern of TCR
activation of PKB was seen in quiescent human peripheral
blood-derived T lymphocytes (Fig. 1B).
Previous studies have shown that PKB is activated by IL-2.
We wished therefore to compare the magnitude of TCR acti-
vation of PKB in human T cells with the response to IL-2.
Since primary T cells do not express IL-2 receptors, we used
IL-2 receptor positive human peripheral blood-derived T lym-
phocytes, quiesced by cytokine deprivation and that were ex-
posed to either IL-2 to ligate IL-2 receptor or UCHT1 to
trigger the TCR complex. The experiment in Fig. 1C shows
that both the TCR and IL-2 can activate PKB and moreover,
the PKB response initiated by IL-2 or the TCR in human
T cells are comparable.
3.2. Antigen receptor regulation of PKB is regulated by PI3K
To assess the involvement of PI3K in cellular responses we
used pharmacological inhibitors of this enzyme. The data in
Fig. 2A show that the PI3K inhibitor LY294002 prevents
both the immediate and sustained PKB activation response
seen in TCR activated cells. An endogenous substrate for
PKB is serine 21 in GSK3K [23]. GSK3 proteins isolated
from quiescent T cells are not reactive with an anti-Ser21
phospho speci¢c antibody but are strongly reactive with the
GSK3K present in cell lysates prepared from TCR triggered
cells or from cells activated with IL-2 (Fig. 2B). LY294002
prevented TCR-induced phosphorylation of the PKB sub-
strate GSK3K (Fig. 2B). Inhibition of PI3K also prevents
IL-2-induced phosphorylation of the PKB substrate GSK3K
In further experiments we explored the selectivity of
LY294002 on the activation of serine kinases by antigen re-
ceptors. Antigen receptors regulate the activity of diacylgly-
cerol-regulated kinases of the protein kinase C superfamily. In
particular, a major target for antigen receptor signals is the
kinase PKD/PKCW whose activity can be readily monitored
by Western blot analysis with an antibody speci¢c for phos-
Fig. 1. The TCR activates PKB. Human primary T cells (A) and quiescent human T lymphoblasts (B,C) were stimulated or not with the anti-
CD3 antibody (UCHT1, 10 Wg/ml) or rIL-2 (20 ng/ml) for the indicated times. Proteins from total cell lysates were separated by 7.5% SDS^
PAGE and revealed by Western blot analysis using a speci¢c phosphoserine (Ser473) PKB antibody and a pan PKB antibody.
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phoserine 916 an autophosphorylation site in the carboxyter-
minus of this enzyme [25]. The data in Fig. 2C show that
LY294002 does not prevent TCR activation of PKD.
3.3. Antigen receptor regulation of S6k1
PKB activation is mediated by the PI3K-dependent protein
kinase PDK1. It was previously shown that this kinase also
regulates the activity of S6k1 because it phosphorylates the
critical residue serine 229 in the activation loop of the cata-
lytic domain of the enzyme [12]. Phosphorylated and active
p70 S6k1 has reduced electrophoretic mobility in SDS^PAGE
gels: the inactive enzyme in T cells typically migrates as a
doublet that is clearly distinct from the hyperphosphorylated
active enzyme [26]. The data in Fig. 3A show that in quiescent
T cells, p70S6k1 migrates predominantly as a doublet whereas
in TCR activated cells four discrete phosphoforms of the en-
zyme can be readily discerned within 10 min of TCR ligation.
TCR activation of p70S6k1 can be seen within 5 min of TCR
engagement, is maximal within 10 min and is dependent on
PI3K activity since it is abrogated when T cells are treated
Fig. 2. PI3K inhibitors selectively block TCR activation of PKB and GSK-3K. Quiescent T blasts were stimulated or not with UCHT1 (10 Wg/
ml) or rIL-2 (20 ng/ml) for the indicated times following a 30-min pre-incubation in the presence or absence of PI-3 kinase inhibitor
(LY294002, 5 WM) as indicated. Proteins from total cell lysates were separated on 7.5% SDS^PAGE. Blots were revealed by Western blot anal-
ysis using a speci¢c phosphoserine (Ser473) PKB antibody and an anti-PKB antibody (A), a phosphoserine (Ser21) GSK-3K antibody and a
pan GSK-3 antibody (B) and a phosphoserine (Ser916) PKD antibody and a pan PKD antibody (C).
Fig. 3. The TCR regulates S6K1. E¡ect of pretreatment of T blasts with LY294002 or rapamycin compounds on the activation S6K1 induced
by TCR crosslinking or rIL-2. Quiescent T blasts were stimulated or not with UCHT1 (10 Wg/ml) (A and B) or rIL-2 (20 ng/ml) (C) for the in-
dicated times following a 30-min preincubation in the presence or absence of LY294002 or rapamycin (20 ng/ml) as indicated. Proteins from to-
tal cell lysates were separated by SDS^PAGE (10% acrylamide/0.1% bis) to resolve the di¡erent S6k1 isoforms. The blot was revealed by West-
ern blot analysis using speci¢c S6k1 antisera.
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with the PI3K inhibitor LY294002 (Fig. 3B). In T lympho-
cytes, p70S6k1 is typically thought of as an IL-2 stimulated
serine kinase [27]. In the current experiment the ability of
TCR ligation to activate p70S6k1 was compared with the
cellular response to IL-2. The results in Fig. 3C show that
the kinetics of the IL-2/S6k1 response is slightly slower than
the TCR response but this is a subtle e¡ect: the TCR response
can be easily seen in cells activated for 5 min whereas 10 min
is required to readily detect IL-2 activation of this enzyme.
The key point is that the magnitude of the TCR/S6k1 re-
sponse is comparable to the response induced by IL-2.
S6k1 is one of the major cellular targets for the immuno-
suppressant rapamycin and it was recognised several years
ago that IL-2 activation of p70S6k was blocked by rapamycin
[28]. Rapamycin is a drug that blocks T cell activation and
clonal expansion in vivo and is used therapeutically as an
immunosuppressant following organ transplantation. The
data in Fig. 3B show that TCR activation of p70S6k1 is in-
hibited by rapamycin. The S6k1 antisera recognises two iso-
forms of S6k1; one migrating at 70 kDa and the other mi-
grating at 85 kDa. The 85 kDa isoform of S6k1 is a splice
variant that has a classic nuclear localisation sequence that
restricts its expression to the nuclear compartment. Interest-
ingly, the data in Fig. 3A show that TCR engagement triggers
a parallel engagement of both the cytosolic p70 and the nu-
clear p85 S6k1 isoforms in T cells. Moreover stimulation of
both isoforms is sensitive to inhibition by the PI3K inhibitor
Ly294002 and is sensitive to rapamycin.
4. Discussion
The present study has explored the ability of the T cell
antigen receptor to regulate the activity of two PI3K-con-
trolled serine kinases PKB/Akt and S6k1. Biochemical links
between the TCR and PI3K have been recognised for many
years [4^6] but downstream targets for PI3K in the context of
antigen receptor signalling in T cells have not been well de-
¢ned. Importantly the present experiments have been per-
formed in primary peripheral blood-derived human T cells
rather than in transformed cell lines. The data show that
triggering of the TCR complex causes a rapid and sustained
activation of AKT/PKB and S6k1. These responses were de-
pendent on the activity of PI3K. The present data show also
that the TCR can induce phosphorylation on serine 21 of
GSK3K, an endogenous substrate of PKB. The phosphoryla-
tion of GSK3 on serine 21 inactivates this enzyme. GSK3 was
identi¢ed initially as a regulator of glycogen metabolism but it
is now recognised that it has broader functions in the control
of transcription factors: interactions between GSK3 and L-
catenin regulate activity of the T cell factor-lymphoid en-
hancer factor (Tcf-Lef) [29]. GSK3 can also control the nu-
clear export of NFAT; transcription factors involved in cyto-
kine gene induction [24]. The phosphorylation and
inactivation of GSK3 mediated by the TCR/PKB axis would
favour nuclear retention of NFAT in the nucleus and increase
its transcriptional activity.
The second PI3K-regulated serine kinase shown herein to
be activated by the TCR is S6k1. One interesting feature
about TCR regulation of S6k1 is that TCR engagement trig-
gers a parallel engagement of both the 70 kDa and 85 kDa
isoforms of this enzyme. The 85 kDa isoform of S6k1 has a
classic nuclear localisation sequence restricting its expression
to the nuclear compartment [30]. PI3K-dependent activation
of p85 S6k1 by the TCR is thus a clear indication that PI3K
can couple the TCR to serine kinases in the nucleus. S6 ki-
nases are well documented as targets for cytokine signalling in
lymphocytes but have not been recognised as a target for
antigen receptor signalling possibly because many studies of
TCR signal transduction are performed on transformed cell
lines either T leukaemic cells lines or T cell hybridomas. These
are invaluable models for antigen receptor regulation of tyro-
sine kinases but they cause problems in the analysis of S6k
regulation. For example, Jurkat cells one of the most fre-
quently used model cell systems for exploration of TCR signal
transduction have basely high constitutively active S6k that
cannot be further activated by any exogenous stimuli. The
functional relevance of S6k1 regulation by the TCR stems
from the critical role that this kinase has in the regulation
of protein synthesis and cell growth. For example, S6k1 has
been shown to regulate the activity of E2F transcription fac-
tors in T cells [26]. E2Fs regulation play an important role in
controlling ordered progression through the cell cycle. The
role of S6k as an essential regulator of cell growth and cell
size has been well documented in lower eukaryotes such as
Drosophila [18]. Primary T cells are extremely small, metabol-
ically inactive cells and an increase in protein synthesis and
protein turnover is essential for the cell growth that enables
T cells to reach the necessary size for optimum function and
proliferation. The ability of the TCR to activate S6k1 shows
that an evolutionarily conserved pathway for the regulation of
cell growth is under the control of the speci¢c immune system
in T lymphocytes. S6k1 control enables the antigen receptor
to initiate the changes in protein synthesis and cell growth
that will allow the T cell to develop its functional programme.
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